Sage Therapeutics Shares Slide Premarket After Zurzuvae MDD Setback
By Colin Kellaher
Shares of Sage Therapeutics tumbled more than 45% in premarket trading Monday after the U.S. Food and Drug Administration rejected a key use for the biopharmaceutical company's depression drug with partner Biogen.
Sage and Biogen were seeking FDA approval of Zurzuvae, a fast-acting depression drug, for major depressive disorder, or MDD, and postpartum depression.
The agency late Friday gave a green light to Zurzuvae in postpartum depression but declined to approve the drug in the much larger indication of MDD, saying more studies were needed.
Biogen and Sage, both based in Cambridge, Mass., late Friday said they were reviewing their next steps for Zurzuvae in MDD, and Sage on Monday said it is evaluating steps to extend its cash runway, including a pipeline prioritization and a workforce reorganization.
Sage shares, which closed Friday at $36.10, were recently down nearly 47% to $19.24 in premarket trading, while shares of Biogen slipped 3% to $261.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 07, 2023 08:03 ET (12:03 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure